Atossa Therapeutics

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Redcliffe,,Queensland,,Australia,-,May,14,2018:,Domino's,Pizza,Store

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ATOS

KRYS

PLAY

SUPN

Domino&#39;s Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday

Screenshot 2024-04-01 at 9.57.34 PM

Biotech

General

This Biotech Works On All Phases Of Breast Cancer, From Prevention To Post Surgery

This Drug Developer Is Dedicated To “Transforming The Breast Cancer Paradigm”

Penny Stocks

Interview

Dr. Steven Quay MD, PhD, President &amp; CEO of Atossa Therapeutics Inc. (NASDAQ: ATOS) was recently interviewed by Benzinga.

This Drug Developer Is Dedicated To &#34;Transforming The Breast Cancer Paradigm&#34;

Atossa Therapeutics Inc

Atos SE

ATOS ORIGIN SA UNSP/ADR by Atos Origin SA

Press Releases

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Health Care

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Applauds U.S. Surgeon General's Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Legal

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

Management

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Aadi Bioscience

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Anixa Biosciences

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Biomea Fusion

Cabaletta Bio

Climb Bio

Caribou Biosciences

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Elutia

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

HilleVax

TuHURA Biosciences

Immunic

Invivyd

Lexeo Therapeutics

Regulus Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Sutro Biopharma

TScan Therapeutics

Vigil Neuroscience

Vaxart

XBiotech

HC Wainwright & Co.

Ascendiant Capital

Atossa Genetics

Comments

Atossa Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga